Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab Withdrawal in Plaque Psoriasis
NCT04537689Phase 4Recruiting
- Sponsor
- Singapore General Hospital
- Start
- Dec 2020
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ixekizumab in plaque psoriasis, sponsored by Singapore General Hospital. Started Dec 2020; status: recruiting.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04537689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04537689.